Farxiga Side Effects: Incidence Rates Across Clinical Trials

How Dapagliflozin's Mechanism Shapes Its Side-Effect Profile

Dapagliflozin blocks the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, causing roughly 60 to 80 g of glucose to spill into the urine per day. That glucosuria creates an environment favorable to genital and urinary tract infections, while the accompanying osmotic diuresis drives the volume-depletion events seen across trials. The FDA prescribing label lists genital mycotic infections, urinary tract infections (UTIs), and volume depletion as the most clinically common adverse reactions.

The Glucose-Spill Mechanism

Blocking SGLT2 reduces renal glucose reabsorption by approximately 40 to 50% in healthy volunteers, producing a predictable caloric deficit and osmotic load. A 2019 pharmacodynamic review in the Clinical Journal of the American Society of Nephrology confirmed that this mechanism is active even at estimated GFR (eGFR) as low as 25 mL/min/1.73 m², which matters for interpreting adverse event rates in the CKD subpopulation.

Why Adverse Event Rates Differ Across Indications

Patients enrolled in heart failure and CKD trials are older, more frequently male, and carry heavier comorbidity burdens than typical T2DM trial populations. A 2021 analysis in JACC: Heart Failure noted that baseline eGFR below 45 mL/min/1.73 m² attenuates the glycosuric response but does not eliminate the risk of volume depletion or Fournier gangrene. This explains why adverse event rates in DAPA-HF and DAPA-CKD sometimes differ from those in DECLARE-TIMI 58.

DECLARE-TIMI 58: The Largest Dapagliflozin Safety Dataset

DECLARE-TIMI 58 enrolled 17,160 adults with T2DM who had either established atherosclerotic cardiovascular disease or multiple risk factors, randomized to dapagliflozin 10 mg or placebo, with a median follow-up of 4.2 years. The primary results published in NEJM (Wiviott et al., 2019) remain the single largest dapagliflozin safety repository available.

Genital and Urinary Tract Infections

Genital mycotic infections were the most frequently elevated adverse event. In women, the rate was 6.6% with dapagliflozin versus 1.4% with placebo (absolute risk increase 5.2 percentage points). In men, the rate was 2.7% versus 0.4%. Most cases were mild-to-moderate and responded to standard antifungal therapy without drug discontinuation. Wiviott et al. reported that serious genital infections, including Fournier gangrene, occurred in 6 dapagliflozin patients versus 1 placebo patient, a numerically small but clinically significant signal.

UTI rates were 6.3% versus 5.6%, representing a marginal absolute difference of 0.7 percentage points. The FDA label does not list UTI as a common adverse reaction for this reason, though the label does include a warning for serious UTIs including urosepsis and pyelonephritis.

Diabetic Ketoacidosis

DKA occurred in 0.3% of dapagliflozin-treated patients versus 0.1% of placebo patients in DECLARE-TIMI 58. A dedicated safety analysis in Diabetes Care (Bhatt et al., 2020) found that nearly all DKA events were euglycemic, meaning blood glucose was below 250 mg/dL at presentation, a pattern that can delay diagnosis. Off-label use in type 1 diabetes carries substantially higher DKA rates, estimated at 4 to 6 events per 100 patient-years in systematic reviews. A 2019 meta-analysis in The Lancet Diabetes and Endocrinology quantified the type 1 DKA hazard ratio at 3.93 (95% CI 2.44 to 6.34) relative to placebo across pooled SGLT2 inhibitor data.

Volume Depletion and Hypotension

Volume depletion events (dizziness, orthostatic hypotension, or dehydration-related hospitalization) occurred at 1.5% in the dapagliflozin arm versus 1.2% in placebo across DECLARE-TIMI 58. The prescribing label recommends assessing volume status before initiation and correcting any deficits in patients at risk. Diuretic co-administration raises this risk further; in an FDA review of pooled phase 3 data, patients on background loop diuretics had a 2-fold higher rate of volume-depletion events compared to those without diuretics.

Hypoglycemia

Dapagliflozin does not stimulate insulin secretion, so hypoglycemia rates in DECLARE-TIMI 58 were low: 4.3% for dapagliflozin versus 5.6% for placebo when used on a background of non-sulfonylurea therapy. When added to a sulfonylurea or insulin, however, a pooled analysis of six phase 3 trials published in Diabetes, Obesity and Metabolism found major hypoglycemia rates rising to 1.0 to 1.5 per 100 patient-years.

DAPA-HF: Safety in Heart Failure With Reduced Ejection Fraction

DAPA-HF enrolled 4,744 patients with NYHA class II, IV heart failure and left ventricular ejection fraction (LVEF) <40%, randomized to dapagliflozin 10 mg or placebo. McMurray et al. (NEJM, 2019) reported the primary cardiovascular outcomes, and an accompanying safety analysis in JACC: Heart Failure provided detailed adverse event breakdowns.

Volume Depletion in a Diuretic-Heavy Population

Volume depletion events occurred in 7.5% of dapagliflozin patients versus 6.8% of placebo patients (absolute difference 0.7 percentage points). Despite nearly all patients being on background diuretics, the increase was modest. Serious volume depletion events, requiring intravenous fluid resuscitation or hospitalization, occurred in 1.0% versus 0.7%. McMurray et al. noted that dapagliflozin's diuretic-like effect may partly substitute for, rather than add to, background loop diuretic action.

Renal Adverse Events

Renal adverse events occurred less frequently in the dapagliflozin group (1.6%) than in placebo (2.7%), a finding consistent with the drug's nephroprotective mechanism. A secondary analysis in the European Heart Journal showed that eGFR decline over 18 months was 0.87 mL/min/1.73 m² less steep in the dapagliflozin group, a statistically significant difference (P<0.001).

Genital and Urinary Infections in Heart Failure Patients

Because DAPA-HF enrolled predominantly male patients (77%), genital mycotic infection rates were lower than in DECLARE-TIMI 58: 0.9% dapagliflozin versus 0.1% placebo. UTIs occurred in 3.8% versus 3.7%, an absolute difference of only 0.1 percentage points. Serious UTIs (urosepsis or pyelonephritis) were not significantly elevated.

DAPA-CKD: Safety in Chronic Kidney Disease

DAPA-CKD enrolled 4,304 adults with CKD (eGFR 25 to 75 mL/min/1.73 m²) and albuminuria, approximately one-third of whom did not have T2DM. Heerspink et al. (NEJM, 2020) reported the primary outcomes. The trial was stopped early at a median follow-up of 2.4 years due to clear efficacy.

Serious Adverse Events

Overall serious adverse event rates were 33.1% for dapagliflozin versus 36.8% for placebo, a 3.7 percentage-point reduction favoring the drug, largely driven by fewer renal and cardiovascular hospitalizations. Heerspink et al. attributed most of the reduction to the slower progression of CKD in the treatment arm.

DKA in CKD Patients

DKA occurred in 0.3% of dapagliflozin patients versus 0.2% of placebo patients. The absolute numbers were small (6 events vs. 4 events), but physicians should note that euglycemic DKA may be more likely in CKD because reduced renal clearance of ketones can raise serum levels even without classic hyperglycemia. A 2022 review in the American Journal of Kidney Diseases recommended baseline bicarbonate monitoring and sick-day rules for all SGLT2 inhibitor-treated CKD patients.

Amputations and Peripheral Ischemia

Unlike canagliflozin (which carries an FDA boxed warning for amputations), dapagliflozin did not show a statistically significant amputation signal in DAPA-CKD (0.4% vs. 0.5%) or DECLARE-TIMI 58 (1.0% vs. 1.0%). A 2021 comparative safety analysis in BMJ found no elevated amputation hazard for dapagliflozin versus other SGLT2 inhibitors in a real-world cohort of 309,056 patients.

Fournier Gangrene and Necrotizing Fasciitis

Fournier gangrene (necrotizing fasciitis of the perineum and genitalia) is a rare but life-threatening adverse event associated with all SGLT2 inhibitors. The FDA issued a Drug Safety Communication in 2018 after identifying 12 cases across the class in postmarket reports, 5 of which involved dapagliflozin. Background population rates of Fournier gangrene are estimated at 1.6 cases per 100,000 person-years, so even small absolute numbers represent a meaningful relative signal.

Clinicians should instruct patients to seek immediate evaluation for perineal pain, tenderness, erythema, or swelling, and should discontinue dapagliflozin while arranging urgent surgical consultation. A 2019 postmarket cohort analysis using the FDA Adverse Event Reporting System (FAERS) found that SGLT2 inhibitors were associated with a reporting odds ratio of 6.4 (95% CI 3.2 to 12.7) for Fournier gangrene compared with other antidiabetic agents.

Lower Limb Findings and Bone Fractures

Fracture Risk

Early pooled analyses raised concern about reduced bone mineral density with dapagliflozin. A 2016 systematic review in Osteoporosis International found a small but statistically significant reduction in bone mineral density at the hip (mean difference , 0.6%) over 2 years. Fracture rates in DECLARE-TIMI 58 were 3.0% versus 2.9%, a non-significant difference. Patients with pre-existing osteoporosis or at high fracture risk may warrant baseline DEXA scanning before initiating therapy.

Lower-Extremity Concerns

No boxed warning for amputation exists on the dapagliflozin label, in contrast to canagliflozin. The 2021 ADA Standards of Medical Care in Diabetes note that the class-level amputation risk observed with canagliflozin has not been replicated with dapagliflozin in large outcomes trials.

Renal Function Changes: Acute Drops vs. Long-Term Protection

Dapagliflozin causes an acute, reversible decrease in eGFR of approximately 2 to 5 mL/min/1.73 m² in the first 4 weeks of treatment. This initial drop is hemodynamic (reduced glomerular hyperfiltration) and does not indicate nephrotoxicity. A 2020 analysis from DAPA-CKD in the Journal of the American Society of Nephrology confirmed that the long-term slope of eGFR decline was 0.47 mL/min/1.73 m² per year in the dapagliflozin arm versus 1.39 mL/min/1.73 m² per year in placebo (P<0.001), a finding consistent with genuine nephroprotection over time.

Patients with eGFR <25 mL/min/1.73 m² are not expected to achieve meaningful glycemic benefit, and the prescribing label contraindicates initiation for glycemic control at this threshold, though the drug may still be continued for cardiovascular or renal protection per the 2023 ADA/KDIGO joint guidelines.

Drug Interactions That Modify Adverse Event Risk

Certain co-medications raise specific adverse event probabilities. Insulin and sulfonylureas increase hypoglycemia when combined with dapagliflozin. A pharmacokinetic review in Clinical Pharmacokinetics found no clinically relevant interaction with metformin, linagliptin, or pioglitazone at the pharmacokinetic level, but noted that combined use with loop diuretics could amplify volume depletion. Rifampicin (a strong CYP3A4 and UGT1A9 inducer) reduces dapagliflozin AUC by approximately 22%, which could theoretically reduce both efficacy and adverse event rates simultaneously.

RAAS inhibitors (ACE inhibitors or ARBs) combined with dapagliflozin in CKD patients were associated with a marginal increase in hyperkalemia in DAPA-CKD: 5.3% dapagliflozin versus 5.6% placebo, a non-significant difference. Heerspink et al. concluded that RAAS inhibitor background therapy did not substantially modify the safety profile of dapagliflozin in CKD.

FAERS Postmarket Signals Beyond Trial Data

The FDA Adverse Event Reporting System captures signals that randomized trials often miss because of strict enrollment criteria. As of the most recent public FAERS quarterly data, dapagliflozin ranks among the top-reported drugs for three signals: euglycemic DKA, Fournier gangrene, and urinary tract infections with systemic spread.

A 2020 disproportionality analysis in Drug Safety analyzed 18,286 SGLT2 inhibitor adverse event reports in FAERS and found a reporting odds ratio of 18.0 (95% CI 12.1 to 26.9) for euglycemic DKA across the class, with dapagliflozin contributing 31% of total reports. The analysis also found a reporting odds ratio of 3.2 for serious UTI with systemic involvement. Because FAERS data are voluntary and subject to reporting bias, these signals should be interpreted as hypothesis-generating rather than definitive incidence estimates.

The table below summarizes key adverse event incidence rates drawn from the three largest dapagliflozin randomized controlled trials. Clinicians can use these numbers to frame pre-prescription counseling and set patient expectations.

| Adverse Event | DECLARE-TIMI 58 (DAPA) | DECLARE-TIMI 58 (PBO) | DAPA-HF (DAPA) | DAPA-CKD (DAPA) | |---|---|---|---|---| | Genital mycotic infection (women) | 6.6% | 1.4% | 0.9%* | ~2.1% | | Genital mycotic infection (men) | 2.7% | 0.4% | 0.9%* | ~0.6% | | UTI (any) | 6.3% | 5.6% | 3.8% | 5.2% | | DKA | 0.3% | 0.1% | <0.1% | 0.3% | | Volume depletion (any) | 1.5% | 1.2% | 7.5% | 4.0% | | Amputation | 1.0% | 1.0% | Not reported | 0.4% | | Bone fracture | 3.0% | 2.9% | Not reported | 1.0% |

*DAPA-HF population was 77% male; combined rate shown.

Sources: Wiviott et al., NEJM 2019; McMurray et al., NEJM 2019; Heerspink et al., NEJM 2020.

Special Populations: Pregnancy, Elderly, and Renal Impairment

Pregnancy

Dapagliflozin is contraindicated in the second and third trimesters. The FDA label cites animal data showing renal pelvic and tubular dilatation in offspring exposed during organogenesis. Because human data are sparse, the drug should be discontinued as soon as pregnancy is confirmed. A 2021 pharmacovigilance review in the British Journal of Clinical Pharmacology identified 88 prospectively reported pregnancies with SGLT2 inhibitor exposure; neonatal renal anomalies were reported in 4 cases, though confounding by indication could not be excluded.

Elderly Patients (Age >75 Years)

Volume depletion risk increases substantially in patients over 75. A subgroup analysis of DECLARE-TIMI 58 in Diabetes Care found that participants aged 65 and older experienced volume depletion events at 2.3% versus 1.5% in placebo, a higher absolute risk increase than in younger cohorts. Fall-related injuries were numerically higher but not statistically significant. Clinicians may consider reducing background diuretic doses before initiating dapagliflozin in elderly patients.

Patients With eGFR <45 mL/min/1.73 m²

Glycosuric efficacy falls off as eGFR declines, so metabolic adverse events (hypoglycemia, DKA) are attenuated. Volume depletion risk, however, persists. DAPA-CKD enrolled patients with eGFR as low as 25 mL/min/1.73 m² without a significant increase in acute kidney injury events (3.0% dapagliflozin vs. 4.0% placebo). These data support continued use for renal and cardiovascular indications at lower eGFR thresholds.

Monitoring Recommendations Based on Trial Evidence

The 2023 American Diabetes Association Standards of Care (Section 9, Pharmacologic Approaches) recommend checking eGFR and potassium before initiating dapagliflozin and repeating at 3 months in patients with CKD. Baseline HbA1c, urinalysis, and a review of concomitant diuretic doses are standard practice. A clinical practice guidance from the American College of Cardiology (2022) added that clinicians managing heart failure patients should also review blood pressure, signs of orthostasis, and current loop diuretic dose at each visit during the first 3 months of therapy.

Patients starting dapagliflozin should receive explicit counseling on three points: the need for thorough genital hygiene to reduce mycotic infection risk, the warning signs of DKA (nausea, vomiting, abdominal pain, shortness of breath) regardless of glucose level, and hydration guidance during illness or surgery (so-called "sick-day rules"). The CREDENCE trial experience with canagliflozin, which used structured sick-day guidance, achieved a DKA rate of only 0.3% despite a high-risk CKD population, suggesting that patient education materially reduces this risk.